Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights. Q3 ...
Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic severe ...
Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term ...
4d
Minimally invasive procedure for aortic valve disease has similar outcomes as surgery, study reports
People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...
The PARADIGM Trial builds on Anteris’ existing clinical data from 130 patients previously treated with the DurAVR® THV system, including first-time aortic stenosis cases, valve-in-valve patients, and ...
Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global ...
The results underscore the need to perform CT imaging when deciding between procedures in patients with aortic stenosis.
Dr Pankaj Garg explains how 4D flow cardiac MRI clarifies ‘grey zone’ aortic stenosis and visualises complex flow patterns to ...
Corinne Gregory opens up to PEOPLE about helping her parents choose medical aid in dying and end their lives on the same day. She recalls advocating for their right to die and being by their side in ...
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, a heart health company modernizing cardiovascular drug development, today introduced the three late-stage clinical programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback